ClinicalTrials.gg
TerminatedNCT06091930Updated Oct 14, 2026

A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

A Phase 1 interventional study of BI 765049 and Ezabenlimab in Gastrointestinal Cancer, Lung Cancer and Pancreatic Cancer, sponsored by Boehringer Ingelheim. Terminated at 3 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Primary conditionColorectal NeoplasmsRegistry: Gastrointestinal NeoplasmsReclassifiedWhy we changed it
Registry
Gastrointestinal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colorectal Neoplasms
Why
  1. The study's listed conditions name Colorectal Neoplasms, a narrower term within Gastrointestinal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim — 1 open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Boehringer Ingelheim.

Enrollment
10th of 14
21 · median 57
Started
2024
with 1 other
Phase 1
5 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 5 in phase 1, and was the 12th registered.

Colorectal Neoplasms

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 14 studies in Colorectal Neoplasms by Boehringer Ingelheim is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Colorectal Neoplasms by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This is a study in adults from Asia with different types of advanced cancer (solid tumours). People can join the study if they have cancer of the stomach, large bowel and rectum, pancreas, liver, head and neck or non-small cell lung cancer. This is a study for people for whom previous treatment was not successful or no treatment exists. People can participate if their tumour has the B7-H6 marker.

The purpose of this study is to find the highest dose of BI 765049 that people with advanced cancer can tolerate when taken (alone and) together with ezabenlimab. Another purpose is to check whether BI 765049 taken (alone and) together with ezabenlimab can make tumours shrink. Both medicines may help the immune system fight cancer.

Participants can stay in the study up to 3 years, as long as they can tolerate it and can benefit from it. During this time, they visit the study site about every 3 weeks. At the study site they get BI 765049 alone or in combination with ezabenlimab as an infusion into a vein. BI 765049 is given in 3-week cycles, ezabenlimab is given once every 3 weeks.

The doctors check the health of the participants and note any health problems that could have been caused by BI 765049 or ezabenlimab. Doctors regularly check the size of the tumour and check whether it has spread to other parts of the body.

03

Conditions studied

  • Gastrointestinal Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer
  • Head and Neck Cancer
  • Liver Cancer
04

In context

Colorectal Neoplasms Reclassified

6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

This study's enrollment of 21 is below the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Compared within Colorectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated, written inform consent form (ICF) (ICF1 for B7-H6 testing for all patients except those with colorectal cancer (CRC); ICF2 for all patients) describing the study in accordance with International Council on Harmonisation Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
  • ≥18 years of age at the time of signature on the ICFs (ICF1 and ICF2).
  • or cytologically confirmed diagnosis of an advanced, unresectable, and/or gastrointestinal cancer, colorectal cancer, pancreatic cancer, liver cancer, head and neck cancer, or lung cancer.
  • Disease progression despite conventional treatment, intolerant to or not a candidate for conventional treatment, or with a tumour for which no conventional treatment exists.
  • Agree to the collection of tumour samples (as slides from archival diagnostic samples or fresh tumour ) for confirmation of B7-H6 expression at Screening Visit 02 for colorectal cancer (CRC) patients or at Screening Visit 01 for all other patients.
  • Confirmed B7-H6 expression on tumour tissue sample (archived or fresh tumour biopsy) based on central pathology review except for patients diagnosed with advanced or metastatic colorectal cancer (CRC).
  • (ECOG) performance status of 0 or 1.
  • At least one evaluable target lesion as defined per (RECIST v1.1), outside of the central nervous system (CNS), separate from any lesion(s) identified for tumour biopsy. Tumour lesions that have been irradiated ≥28 days before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions only in the absence of that have not been irradiated.
  • Further inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of a major surgery within 28 days prior to first dose of BI 765049 (major according to the Investigator's assessment).
  • Previous or concomitant other than the one treated in this trial within the last 3 years except:

    • Effectively treated non-melanoma skin cancers
    • Effectively treated carcinoma in situ of the cervix
    • Effectively treated ductal carcinoma in situ
    • Other effectively treated malignancy that is considered cured by local treatment
  • Known or spinal cord compression due to disease.
  • Require anticoagulant treatment which cannot be safely interrupted, if medically needed for a study procedure (e.g., ) based on the opinion of the Investigator.
  • virus (HCV) infection, defined as:

    • Currently receiving curative antiviral treatment for HCV infection, and/or
    • HCV viral load is above the limit of quantification (HCV Ribonucleic acid (RNA) positive)
  • virus (HBV) infection with the following laboratory evidence: positive results of hepatitis B surface (HBs) antigen and presence of Hepatitis B core (HBc) antibody together with HBV-deoxyribonucleic acid (DNA).
  • Presence of any infection requiring systemic antimicrobial treatment within 7 days prior to first dose of trial medication. Patients who have any clinical signs of infection (e.g. fever or leukocytosis) within 48 hours prior to first dose of trial medication are not eligible.
  • Patients with known history of (HIV) infection who meet one or more of the following criteria:

    • Cluster of differentiation 4 (CD4+) count \<350 cells/μL (local lab assessment)
    • Viral load >400 copies/mL (local lab assessment)
    • Not receiving antiretroviral therapy
    • Receiving established antiretroviral therapy for less than four weeks prior to the start of study treatment
    • History of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months prior to start of study treatment Patients with a history of HIV who do not meet any of the criteria above are eligible to participate, but the patient must be under the care of a HIV/Infectious Diseases specialist, or a HIV/Infectious Diseases specialist must be consulted prior to inclusion.
  • Further exclusion criteria apply
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Part I: BI 765049

    BI 765049 monotherapy - dose escalation

    Drug: BI 765049

  • Experimental
    Part II: BI 765049

    BI 765049 monotherapy - dose expansion

    Drug: BI 765049

  • Experimental
    Part III: BI 765049 + ezabenlimab

    BI 765049 + ezabenlimab combination therapy - dose escalation

    Drug: BI 765049 · Drug: Ezabenlimab

  • Experimental
    Part IV: BI 765049 + ezabenlimab

    BI 765049 + ezabenlimab combination therapy - dose expansion

    Drug: BI 765049 · Drug: Ezabenlimab

Interventions

07

What researchers measure

Primary outcomes

  1. Part I: Occurrence of dose-limiting toxicity (DLTs) during the maximum tolerated dose (MTD) evaluation period for BI 765049 monotherapy

    Time frame: One treatment cycle, defined as 3 weeks after first administration of BI 765049 or 1 week after the administration of first full dose of BI 765049, whichever is longer

  2. Part II: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1)

    Objective response will be determined by the Investigator in patients with measurable disease and will be defined as the best overall response of complete response (CR) or partial response (PR), from the first administration of trial medication until the earliest of progressive disease (PD), death, last evaluable tumour assessment before the start of subsequent anti-cancer therapy, lost to follow-up, or withdrawal of consent.

    Time frame: Up to month 36

  3. Part III: Occurrence of dose-limiting toxicity (DLTs) during the maximum tolerated dose (MTD) evaluation period for BI 765049 in combination with ezabenlimab

    Time frame: From first BI 765049 administration to 1 week after the first ezabenlimab dose

  4. Part IV: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1)

    Time frame: Up to month 36

Secondary outcomes

  1. Part I: Maximum measured concentration of BI 765049 (Cmax) after first administration

    Time frame: Up to 1 day

  2. Part I: Maximum measured concentration of BI 765049 (Cmax) after multiple administrations

    Time frame: Up to month 37

  3. Part III: Maximum measured concentration of BI 765049 (Cmax) after the first administration

    Time frame: Up to 1 day

  4. Part III: Maximum measured concentration of BI 765049 (Cmax) after multiple administrations

    Time frame: Up to month 37

  5. Part I: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after the first administration

    Time frame: Up to 1 day

  6. Part I: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations

    Time frame: Up to month 37

  7. Part III: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after the first administration

    Time frame: Up to 1 day

  8. Part III: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations

    Time frame: Up to month 37

  9. Part I: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1)

    Objective response will be determined by the Investigator in patients with measurable disease who have been treated with either BI 765049 monotherapy or BI 765049 in combination with ezabenlimab and will be defined as the best overall response of complete response (CR) or partial response (PR), according to response evaluation criteria in solid tumors (RECIST v1.1). from the first administration of trial medication until the earliest of progressive disease (PD), death, or last evaluable tumour assessment before the start of subsequent anti-cancer therapy, lost to follow-up, or withdrawal of consent.

    Time frame: Up to month 36

  10. Part III: Objective response based on the response evaluation criteria in solid tumors (RECIST v1.1)

    Time frame: Up to month 36

  11. Part II: Progression free survival (PFS)

    Progression free survival (PFS) will be defined as the time from first treatment administration until tumour progression according to response evaluation criteria in solid tumors (RECIST v1.1) as determined by the Investigator or death from any cause, whichever occurs earlier.

    Time frame: Up to month 36

  12. Part IV: Progression free survival (PFS)

    Time frame: Up to month 36

  13. Part II: Duration of response

    Duration of response will be defined as the time from a patient's first documented complete response (CR) or partial response (PR), according to response evaluation criteria in solid tumors (RECIST v1.1), until the earliest of disease progression, or death.

    Time frame: Up to month 36

  14. Part IV: Duration of response

    Time frame: Up to month 36

  15. Part II: Disease control

    Disease control will be defined as best overall response of complete response (CR), partial response (PR) or stable disease (SD) where best overall response is as determined by the Investigator according to response evaluation criteria in solid tumors (RECIST v1.1) from the first administration of trial medication until the earliest of progression disease (PD), death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, lost to follow-up, or withdrawal of consent.

    Time frame: Up to month 36

  16. Part IV: Disease control

    Time frame: Up to month 36

  17. Part II: Objective response based on the immune response evaluation criteria in solid tumors (iRECIST)

    Objective response based on immune response evaluation criteria in solid tumors (iRECIST) criteria will be determined by the Investigator in patients with measurable disease and will be defined as the best overall response of complete response (CR) or partial response (PR), from the first administration of trial medication until the earliest of immune confirmed progressive disease (PD), death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, lost to follow-up, or withdrawal of consent.

    Time frame: Up to month 36

  18. Part IV: Objective response based on the immune response evaluation criteria in solid tumors (iRECIST)

    Time frame: Up to month 36

  19. Part II: Maximum measured concentration of BI 765049 (Cmax) after first administration

    Time frame: Up to 1 day

  20. Part II: Maximum measured concentration of BI 765049 (Cmax) after multiple administrations

    Time frame: Up to month 37

  21. Part IV: Maximum measured concentration of BI 765049 (Cmax) after first administration

    Time frame: Up to 1 day

  22. Part IV: Maximum measured concentration of BI 765049 (Cmax) after multiple administrations

    Time frame: Up to month 37

  23. Part II: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after first administration

    Time frame: Up to 1 day

  24. Part II: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations

    Time frame: Up to month 37

  25. Part IV: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after first administration

    Time frame: Up to 1 day

  26. Part IV: Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ) after multiple administrations

    Time frame: Up to month 37

08

Study locations

3 sites
  • National Cancer Center Hospital East
    Chiba, Kashiwa, 277-8577, Japan
  • National Cancer Center Hospital
    Tokyo, Chuo-ku, 104-0045, Japan
  • Japanese Foundation for Cancer Research
    Tokyo, Koto-ku, 135-8550, Japan
09

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Aug 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Oct 23, 2023
StartActual
Feb 16, 2024
Primary completionActual
Aug 15, 2025
CompletionActual
Feb 2, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06091930
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Feb 16, 2024
Primary completion
Aug 15, 2025
Completion
Feb 2, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049

Start the discussion